The Motley Fool on MSN7d
Is Pfizer Stock a Bargain for Long-Term Investors?Pfizer's non-COVID product revenues surged 14% operationally last quarter. The oncology business delivered exceptional ...
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...
Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.
Evercore ISI analyst Umer Raffat maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares closed ...
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The ...
Pfizer's RSV rollback comes as the space has grown increasingly crowded. Besides marketed vaccines, Sanofi and AstraZeneca sell an antibody to protect infants, with Merck & Co. now eying a piece of ...
Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...
Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; ...
Pfizer's non-COVID product revenues surged 14 ... highlighted by the strong uptake of Padcev. When combined with Merck's Keytruda (pembrolizumab), this therapy has become the most prescribed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback